Homologous Recombination Deficiency Landscape of Breast Cancers and Real-World Effectiveness of Poly ADP-Ribose Polymerase Inhibitors in Patients With Somatic BRCA1/2, Germline PALB2, or Homologous ...

The first-in-class PARP1-selective inhibitor saruparib demonstrated encouraging early efficacy and a favorable safety profile in patients with homologous recombination repair (HRR)-deficient breast ...

Homologous recombination deficiency (HRD) is a well-described phenotype of some prostate cancers; however, current biomarkers for HRD are imperfect and rely on detection of single gene alterations in ...

Tokyo, Japan – Researchers from Tokyo Metropolitan University have been studying DNA repair by homologous recombination, where the RecA protein repairs breaks in double-stranded DNA by incorporating a ...

A whole-genome sequencing approach shows early promise over current commercial methods for identifying more patients likely to benefit from PARP inhibitor cancer treatments, according to a study led ...

The metabolite, Ding noted, potentiates anti-tumor immunity and blunts the ability of homologous recombination repair, which means GDP-M impedes a tumor's ability to repair breaks in its DNA.

AMPLITUDE is the first clinical trial to evaluate potential therapies for patients with mHSPC and known HRR gene alterations, with positive results supporting the niraparib-based combination regimen a ...

Please provide your email address to receive an email when new articles are posted on . Adding niraparib to abiraterone acetate and prednisone lowered risk for cancer growth by 37% among certain ...

A recent study, undertaken by researchers at the Tokyo Metropolitan University and the Tokyo Metropolitan Institute of Medical Science (both Japan), unravels key steps in the process of homologous ...

TALAPRO-2 trial shows Talzenna plus Xtandi improves median OS by 8.8 months in mCRPC patients, reducing death risk by 20.4%. HRR-deficient patients benefit more, with a 38% reduction in death risk and ...